R-2HG also effectively suppresses aerobic glycolysis in IDH-wild-type leukemia cells by targeting the FTO/m6A/YTHDF2 signaling pathway to downregulate the expression of two critical glycolytic genes, PFKP and LDHB, which contributes to its antitumor effects [73]. The gene discussed is FTO; the disease is leukemia.